

Sanofi  
Form 6-K  
April 11, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2016**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

**54, rue La Boétie, 75008 Paris, FRANCE**

**(Address of principal executive offices)**

Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-

In March and April 2016, Sanofi issued the statements attached hereto as Exhibit 99.1 to 99.6 which are incorporated herein by reference.

**Exhibit List**

Exhibit	
No.	Description
Exhibit 99.1	Press release dated March 16, 2016: Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform
Exhibit 99.2	Press release dated March 16, 2016: Sanofi and Regeneron Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent <sup>®</sup> (alirocumab) Injection and Will Appeal
Exhibit 99.3	Press release dated March 23, 2016: Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent <sup>®</sup> (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Exhibit 99.4	Press release dated March 29, 2016: Sanofi successfully prices EUR 1.8 billion bond issue
Exhibit 99.5	Press release dated April 1, 2016: Sanofi and Regeneron Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Exhibit 99.6	Press release dated April 4, 2016: World's First Public Dengue Immunization Program Starts in the Philippines

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 11, 2016

SANOFI

By /S/ Alexandra Roger  
Name: Alexandra Roger  
Title: Head of Securities Law and Capital Markets

**Exhibit Index**

Exhibit	
No.	Description
Exhibit 99.1	Press release dated March 16, 2016: Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform
Exhibit 99.2	Press release dated March 16, 2016: Sanofi and Regeneron Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
Exhibit 99.3	Press release dated March 23, 2016: Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Exhibit 99.4	Press release dated March 29, 2016: Sanofi successfully prices EUR 1.8 billion bond issue
Exhibit 99.5	Press release dated April 1, 2016: Sanofi and Regeneron Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Exhibit 99.6	Press release dated April 4, 2016: World's First Public Dengue Immunization Program Starts in the Philippines